POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in Head and Neck cancer

HOX genes are master regulators of organ morphogenesis and cell differentiation during embryonic development, and continue to be expressed throughout post-natal life. To test the hypothesis that HOX genes are dysregulated in head and neck squamous cell carcinoma (HNSCC) we defined their expression profile, and investigated the function, transcriptional regulation and clinical relevance of a subset of highly expressed HOXD genes. Two HOXD genes, D10 and D11, showed strikingly high levels in HNSCC cell lines, patient tumor samples and publicly available datasets. Knockdown of HOXD10 in HNSCC cells caused decreased proliferation and invasion, whereas knockdown of HOXD11 reduced only invasion. POU2F1 consensus sequences were identified in the 5′ DNA of HOXD10 and D11. Knockdown of POU2F1 significantly reduced expression of HOXD10 and D11 and inhibited HNSCC proliferation. Luciferase reporter constructs of the HOXD10 and D11 promoters confirmed that POU2F1 consensus binding sites are required for optimal promoter activity. Utilizing patient tumor samples a significant association was found between immunohistochemical staining of HOXD10 and both the overall and the disease-specific survival, adding further support that HOXD10 is dysregulated in head and neck cancer. Additional studies are now warranted to fully evaluate HOXD10 as a prognostic tool in head and neck cancers.

[1]  T. Jin,et al.  POU Homeodomain Protein OCT1 Is Implicated in the Expression of the Caudal-related Homeobox Gene Cdx-2* , 2001, The Journal of Biological Chemistry.

[2]  B. O'Sullivan,et al.  Cancers of the upper aerodigestive tract in Ontario, Canada, and the United States , 2000, Cancer.

[3]  Ji‐you Li,et al.  Expression of 11 HOX genes is deregulated in esophageal squamous cell carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  T. Kondoh,et al.  MicroRNA‐10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC , 2009, International journal of cancer.

[5]  S. Lippman,et al.  Head and Neck Cancer , 1993, Cancer treatment and research.

[6]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[7]  E. Benveniste,et al.  Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions , 2000, Oncogene.

[8]  Kevin J Harrington,et al.  Targeting HOX and PBX transcription factors in ovarian cancer , 2010, BMC Cancer.

[9]  E. Wingender,et al.  MATCH: A tool for searching transcription factor binding sites in DNA sequences. , 2003, Nucleic acids research.

[10]  Yoko Takahashi,et al.  Dysregulated expression of HOX and ParaHOX genes in human esophageal squamous cell carcinoma. , 2007, Oncology reports.

[11]  Jürgen Borlak,et al.  Transcription profiling of lung adenocarcinomas of c-myc-transgenic mice: Identification of the c-myc regulatory gene network , 2008, BMC Systems Biology.

[12]  R. Morgan,et al.  Targeting the HOX/PBX dimer in breast cancer , 2012, Breast Cancer Research and Treatment.

[13]  P. Speight,et al.  alpha v beta 6 Integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. , 2001, The Journal of investigative dermatology.

[14]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[15]  P. Speight,et al.  αvβ6 Integrin Upregulates Matrix Metalloproteinase 9 and Promotes Migration of Normal Oral Keratinocytes , 2001 .

[16]  Saraswati Sukumar,et al.  The Hox genes and their roles in oncogenesis , 2010, Nature Reviews Cancer.

[17]  Yoko Takahashi,et al.  Aberrant expression of HOX genes in oral dysplasia and squamous cell carcinoma tissues. , 2006, Oncology research.

[18]  D. Grier,et al.  The pathophysiology of HOX genes and their role in cancer , 2005, The Journal of pathology.

[19]  Jun Yu,et al.  Homeobox D10 Gene, a Candidate Tumor Suppressor, Is Downregulated through Promoter Hypermethylation and Associated with Gastric Carcinogenesis , 2012, Molecular medicine.

[20]  F. Couch,et al.  Response: Re: Molecular Basis for Estrogen Receptor α Deficiency in BRCA1-Linked Breast Cancer , 2007 .

[21]  C. Myers,et al.  Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model. , 2005, Cancer research.

[22]  R. Morgan,et al.  Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. , 2007, Cancer research.

[23]  A. Shakya,et al.  Oct1 Is a Switchable, Bipotential Stabilizer of Repressed and Inducible Transcriptional States* , 2010, The Journal of Biological Chemistry.

[24]  Alexander E. Kel,et al.  MATCHTM: a tool for searching transcription factor binding sites in DNA sequences , 2003, Nucleic Acids Res..

[25]  F. Zhao,et al.  Cloning, genomic organization, expression, and effect on beta-casein promoter activity of a novel isoform of the mouse Oct-1 transcription factor. , 2004, Gene.

[26]  Y. Hayashi,et al.  Successful treatment of acute myelomonocytic leukaemia with NUP98–HOXD11 fusion transcripts and monitoring of minimal residual disease , 2003, British journal of haematology.

[27]  F. Couch,et al.  Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. , 2007, Journal of the National Cancer Institute.

[28]  Denis Duboule,et al.  Duplications of hox gene clusters and the emergence of vertebrates. , 2013, Developmental biology.

[29]  S. Paik,et al.  Octamer motif is required for the NF-kappaB-mediated induction of the inducible nitric oxide synthase gene expression in RAW 264.7 macrophages. , 1999, Molecules and cells.

[30]  R. Morgan,et al.  Targeting HOX transcription factors in prostate cancer , 2014, BMC Urology.